公开(公告)号：US20030069196A1

公开(公告)日：2003-04-10

申请号：US10004633

申请日：2001-12-04

Applicant: Millennium Pharmaceuticals, Inc.

Inventor： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

IPC: A61K048/00 ,  C07H021/04

CPC classification number: C12N15/8509 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0325 ,  A01K2267/0368 ,  A01K2267/0375 ,  A01K2267/0381 ,  A01K2267/0387 ,  A01K2267/0393 ,  A61K38/00 ,  C07K14/47 ,  C07K14/70503 ,  C07K19/00 ,  C07K2319/00 ,  C12N9/6467 ,  C12N9/6472 ,  C12Q1/6809

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

公开(公告)号：US06277955B1

公开(公告)日：2001-08-21

申请号：US09472579

申请日：1999-12-27

Applicant: Roland Staud

Inventor： Roland Staud

IPC: A61K3804

CPC classification number: C12N9/6467 ,  A61K38/00 ,  C07K14/4713 ,  G01N33/564 ,  G01N2333/96411 ,  G01N2800/101 ,  Y10S435/81

Abstract: The subject invention pertains to the identification of peptides useful in the detection and treatment of Wegener's granulomatosis.

Abstract translation: 本发明涉及可用于检测和治疗韦格纳肉芽肿病的肽的鉴定。

公开(公告)号：US5492314A

公开(公告)日：1996-02-20

申请号：US398833

申请日：1995-03-06

Applicant: David B. Drennen

Inventor： David B. Drennen

IPC: A01K67/027 ,  A61K38/00 ,  A61K39/395 ,  A61K48/00 ,  A61P3/08 ,  A61P3/10 ,  A61P29/00 ,  A61P31/04 ,  A61P37/00 ,  A61P37/08 ,  B60G13/00 ,  C07K14/52 ,  C07K14/705 ,  C07K16/24 ,  C07K19/00 ,  C12N1/21 ,  C12N5/10 ,  C12N7/01 ,  C12N9/64 ,  C12N15/09 ,  C12N15/85 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/564 ,  B60G7/02 ,  F16F3/08

CPC classification number: C07K14/70503 ,  A01K67/0275 ,  B60G13/003 ,  C07K19/00 ,  C12N15/8509 ,  C12N9/6467 ,  C12N9/6472 ,  C12Q1/6809 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2267/0387 ,  A61K38/00 ,  C07K2319/00

Abstract: A top hydro-pneumatic suspension mount is embodied in a single path preloaded shear compression arrangement achieved by positioning a rate plate between the upper jounce plate and the molding assembly thereby providing a digressive rate performance concurrently providing stiff performance for supporting the vehicle and resilient performance for isolating vertical road input loads.

Abstract translation: 顶部液压气动悬挂支架体现在单路径预加载的剪切压缩装置中，其通过在上部动态板和模制组件之间定位速率板而实现，从而提供离轴速率性能，同时提供用于支撑车辆的刚性性能和弹性性能 隔离垂直道路输入负载。

公开(公告)号：US4973555A

公开(公告)日：1990-11-27

申请号：US948248

申请日：1986-12-31

Applicant: Irving L. Weissman ,  Howard K. Gershenfeld

Inventor： Irving L. Weissman ,  Howard K. Gershenfeld

IPC: A61K38/00 ,  C07K16/40 ,  C12N1/21 ,  C12N9/64 ,  C12N15/57

CPC classification number: C12N9/6467 ,  C07K16/40 ,  A61K38/00

Abstract: Novel human serine proteases are provided characterized by expression in cytotoxic killer cells, being about 25.8kD, and having the amino acid residues of the serine protease charge-relay catalytic mechanism conserved. The proteases can be produced by recombinant DNA technology. The cDNA is also provided.

Abstract translation: 提供了新的人丝氨酸蛋白酶，其特征在于在细胞毒性杀伤细胞中表达，约25.8kD，并且具有丝氨酸蛋白酶电荷 - 中继催化机制的氨基酸残基保守。 蛋白酶可以通过重组DNA技术生产。 还提供cDNA。

公开(公告)号：US20180201918A1

公开(公告)日：2018-07-19

申请号：US15916743

申请日：2018-03-09

Applicant: Research Development Foundation

Inventor： Michael G. ROSENBLUM ,  Khalid Amanali MOHAMEDALI ,  Lawrence H. CHEUNG

IPC: C12N9/64 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C07K14/47 ,  C07K14/00

CPC classification number: C12N9/6467 ,  C07K14/001 ,  C07K14/4747 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/30 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/03 ,  C07K2319/10 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/50 ,  C07K2319/55 ,  C12N9/6424

Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

公开(公告)号：US20180022831A1

公开(公告)日：2018-01-25

申请号：US15547404

申请日：2016-01-29

Applicant: University of Massachusetts

Inventor： Vincent M. Rotello ,  Rubul Mout

IPC: C07K17/14 ,  C12N9/22 ,  C12N15/90 ,  C12N9/64 ,  C12N15/113 ,  C12N9/96 ,  C12N9/12

CPC classification number: C07K17/14 ,  A61K47/6923 ,  C12N9/1241 ,  C12N9/22 ,  C12N9/6467 ,  C12N9/96 ,  C12N15/113 ,  C12N15/907 ,  C12N2310/20 ,  C12Y304/21078

Abstract: Various embodiments disclosed relate to a nanoparticle-protein complex for intracellular protein delivery. In various embodiments, the present invention provides a nanoparticle-protein complex including a nanoparticle including an amine-containing ligand. The nanoparticle-protein complex also includes a protein comprising a carboxylic acid-containing tag.

公开(公告)号：US20170253650A1

公开(公告)日：2017-09-07

申请号：US15507173

申请日：2015-08-21

Applicant: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.

Inventor： Rolf Fendel ,  Stephanie Kapelski ,  Stefan Barth ,  Rainer Fischer ,  Andreas Reimann

IPC: C07K16/20 ,  C12N9/64

CPC classification number: C07K16/205 ,  A61K47/6815 ,  A61K47/6835 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C12N9/6467 ,  C12Y304/21079

Abstract: The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against Plasmodium falciparum (P. falciparum) comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

公开(公告)号：US20150291693A1

公开(公告)日：2015-10-15

申请号：US14440947

申请日：2013-11-04

Applicant: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Inventor： Stefan Barth ,  Sonja Schiffer

IPC: C07K16/28 ,  C12N9/76

CPC classification number: C07K16/283 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/50 ,  C07K2319/55 ,  C12N9/6427 ,  C12N9/6467

Abstract: The technology provided herein relates to novel immunoproteases suitable to induce apotosis in selected diseased target cells, comprising the serine protease granzyme M, and methods for using such cytolytic fusion proteins for the treatment of various diseases, in particular for the treatment of cancer.

Abstract translation: 本文提供的技术涉及适用于诱导选择性病变靶细胞中的凋亡的新型免疫蛋白酶，其包含丝氨酸蛋白酶颗粒酶M，以及使用这种溶细胞融合蛋白用于治疗各种疾病，特别是用于治疗癌症的方法。

公开(公告)号：US20140314760A1

公开(公告)日：2014-10-23

申请号：US14322083

申请日：2014-07-02

Applicant: RESEARCH DEVELOPMENT FOUNDATION

Inventor： Michael G. ROSENBLUM ,  Khalid Amanali MOHAMEDALI ,  Lawrence H. CHEUNG

IPC: C07K14/00 ,  C07K16/00

CPC classification number: C12N9/6467 ,  C07K14/001 ,  C07K14/4747 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/30 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/03 ,  C07K2319/10 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/50 ,  C07K2319/55 ,  C12N9/6424

Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

公开(公告)号：US20120244139A1

公开(公告)日：2012-09-27

申请号：US13506603

申请日：2012-04-30

Applicant: Edwin L. Madison ,  Jack Nguyen ,  Sandra Waugh Ruggles ,  Christopher Thanos

Inventor： Edwin L. Madison ,  Jack Nguyen ,  Sandra Waugh Ruggles ,  Christopher Thanos

IPC: A61K38/48 ,  A61P25/28 ,  A61P1/00 ,  A61P19/02 ,  A61P11/06 ,  A61P25/00 ,  A61P29/00 ,  A61P9/00

CPC classification number: A61K38/482 ,  A61K38/49 ,  C07K2319/00 ,  C12N9/6421 ,  C12N9/6424 ,  C12N9/6467 ,  C12Y304/21109

Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorder.

Abstract translation: 提供了用于调节补体系统的方法和化合物。 特别地，提供抑制补体活化的化合物，并提供促进补体活化的化合物。 这些化合物由于其对补体系统的作用而成为治疗剂。 因此，抑制补体活化的化合物可用于治疗缺血和再灌注障碍，包括心肌梗死和中风，败血症，自身免疫性疾病，炎性疾病和具有炎性成分的疾病，包括阿尔茨海默氏病和其他神经变性疾病。